Paper36840482
Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis.
Hong X and 5 others. Immun Inflamm Dis, 2023. Cited by 21 papers, by iCite.
Cite this record
ConductScience Library. Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis. Papers, record 36840482. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36840482
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Arthritis, Rheumatoid | Major topic |
| Biological Products | Major topic |
| Hepatitis B | Major topic |
| Janus Kinase Inhibitors | Major topic |
| Humans | |
| Hepatitis B Antibodies | |
| Hepatitis B Surface Antigens | |
| Hepatitis B virus | |
| Interleukin-6 | |
| Rituximab | |
| Tumor Necrosis Factor-alpha |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 81760298 | National Natural Science Foundation of China | PubMed | ||
| 2020GXNSFBA297149 | Natural Science Foundation of Guangxi Province | PubMed |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36840482 | Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis. | Immun Inflamm Dis | 2023 | https://conductscience.org/library/papers/36840482 | PubMed |
| 2 | 21719446 | Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. | Ann Rheum Dis | 2011 | https://conductscience.org/library/papers/21719446 | PubMed |
| 3 | 32051458 | Moderate Risk of Hepatitis B Virus Reactivation in HBsAg-/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis. | Sci Rep | 2020 | https://conductscience.org/library/papers/32051458 | PubMed |
| 4 | 31117160 | Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation. | Int J Rheum Dis | 2019 | https://conductscience.org/library/papers/31117160 | PubMed |
| 5 | 25447850 | American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. | Gastroenterology | 2015 | https://conductscience.org/library/papers/25447850 | PubMed |
| 6 | 33028756 | Multidisciplinary Approach to Prevent de novo Hepatitis B in Patients with Rheumatoid Arthritis. | Tohoku J Exp Med | 2020 | https://conductscience.org/library/papers/33028756 | PubMed |
| 7 | 24698305 | Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. | Int J Rheum Dis | 2016 | https://conductscience.org/library/papers/24698305 | PubMed |
| 8 | 25381975 | Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients. | Drug Dev Res | 2014 | https://conductscience.org/library/papers/25381975 | PubMed |
| 9 | 28160426 | Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. | Int J Rheum Dis | 2017 | https://conductscience.org/library/papers/28160426 | PubMed |
| 10 | 25613809 | Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. | Hepatology | 2015 | https://conductscience.org/library/papers/25613809 | PubMed |
| 11 | 28427875 | EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. | J Hepatol | 2017 | https://conductscience.org/library/papers/28427875 | PubMed |
| 12 | 26879359 | Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. | J Rheumatol | 2016 | https://conductscience.org/library/papers/26879359 | PubMed |
| 13 | 29611409 | Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience. | Yonsei Med J | 2018 | https://conductscience.org/library/papers/29611409 | PubMed |
| 14 | 21246383 | Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. | J Gastroenterol | 2011 | https://conductscience.org/library/papers/21246383 | PubMed |
| 15 | 28529116 | Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. | Joint Bone Spine | 2017 | https://conductscience.org/library/papers/28529116 | PubMed |
| 16 | 25447852 | American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. | Gastroenterology | 2015 | https://conductscience.org/library/papers/25447852 | PubMed |
| 17 | 20535784 | Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. | Arthritis Care Res (Hoboken) | 2010 | https://conductscience.org/library/papers/20535784 | PubMed |
| 18 | 30338649 | Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. | Int J Rheum Dis | 2019 | https://conductscience.org/library/papers/30338649 | PubMed |
| 19 | 20668905 | Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. | Mod Rheumatol | 2011 | https://conductscience.org/library/papers/20668905 | PubMed |
| 20 | 24495663 | Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies. | Eur J Intern Med | 2014 | https://conductscience.org/library/papers/24495663 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42370076 | Low value of routine serological screening for hepatitis B in patients with rheumatoid arthritis starting rituximab therapy in a nonendemic region. | EULAR Rheumatol Open | 2026 | https://conductscience.org/library/papers/42370076 | PubMed |
| 42362943 | 2024 Update of the Asia-Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management. | Int J Rheum Dis | 2026 | https://conductscience.org/library/papers/42362943 | PubMed |
| 41239737 | Liver-joint axis: Hepatitis B virus as a contributor to rheumatoid arthritis pathogenesis. | Virulence | 2025 | https://conductscience.org/library/papers/41239737 | PubMed |
| 40385464 | Treatment of Atopic Dermatitis with Upadacitinib in a Patient During Hepatitis C Activity Period. | J Asthma Allergy | 2025 | https://conductscience.org/library/papers/40385464 | PubMed |
| 39998600 | Detection of substantial numbers of latent tuberculosis and positive hepatitis B serology results in rheumatology patients preparing to receive intensified immunosuppressive therapy in a low-prevalence country: why screening still matters. | Clin Rheumatol | 2025 | https://conductscience.org/library/papers/39998600 | PubMed |
| 39850429 | Contradictory Mechanisms of rheumatoid arthritis and hepatitis B virus infection activation. | Heliyon | 2025 | https://conductscience.org/library/papers/39850429 | PubMed |
| 39381733 | Pharmacological considerations in pharmacotherapy of rheumatology patients with liver disease: a brief narrative review. | Reumatologia | 2024 | https://conductscience.org/library/papers/39381733 | PubMed |
| 39014279 | Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review. | Dermatol Ther (Heidelb) | 2024 | https://conductscience.org/library/papers/39014279 | PubMed |
| 38809367 | Implementation of Guideline-Based HBV Reactivation Management in Patients with Chronic HBV Infections of HBsAg or Resolved HBV Infection Undergoing Immunosuppressive Therapy. | Infect Dis Ther | 2024 | https://conductscience.org/library/papers/38809367 | PubMed |
| 38586821 | Upadacitinib-Induced Hepatitis B Reactivation Leading to Liver Transplant. | ACG Case Rep J | 2024 | https://conductscience.org/library/papers/38586821 | PubMed |
| 38257778 | The Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Receiving Tocilizumab: A Systematic Review and Meta-Analysis. | Viruses | 2024 | https://conductscience.org/library/papers/38257778 | PubMed |
| 38216802 | Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors. | Am J Clin Dermatol | 2024 | https://conductscience.org/library/papers/38216802 | PubMed |
| 36840482 | Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis. | Immun Inflamm Dis | 2023 | https://conductscience.org/library/papers/36840482 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| KRT20 | 54474 | PubTator's text mining | https://conductscience.org/library/genes/54474 | NCBI Gene |
| RET | 5979 | PubTator's text mining | https://conductscience.org/library/genes/5979 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36840482
GET https://conductscience.org/api/papers/v1/36840482/references?page=2